Jefferies Sees Nearly 100% Upside in Synta Pharma. (SNTA)
Tweet Send to a FriendGet Alerts SNTA Hot Sheet
Price: $7.50 +0.13%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade SNTA Now!
Jefferies doubled its price target on Synta Pharma. (NASDAQ: SNTA) from $7 to $14 ahead of GALAXY Interim Data.
The firm comments, "Top-line data from the GALAXY lung cancer Phase 2b interim analysis is expected this week, including activity observed in 2 subgroups which we believe to be mutant KRAS and high LDH. For progression-free survival at the interim to be statistically significant, we calculate ganetespib+docetaxel would need to show at least a 55% reduction in risk of progression, which we would see as a highly robust improvement in second-line lung cancer."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $7.24 yesterday, with a 52 week range of $3.02-$7.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Top-line data from the GALAXY lung cancer Phase 2b interim analysis is expected this week, including activity observed in 2 subgroups which we believe to be mutant KRAS and high LDH. For progression-free survival at the interim to be statistically significant, we calculate ganetespib+docetaxel would need to show at least a 55% reduction in risk of progression, which we would see as a highly robust improvement in second-line lung cancer."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $7.24 yesterday, with a 52 week range of $3.02-$7.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
- J.C. Penney (JCP) Stock Already Priced For Recovery - Wells Fargo
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDA, Hot CommentsRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
